Katharina Pomej

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Summative Comorbidities Are Independently Associated With Mortality in Patients With Hepatocellular Carcinoma.

Summative Comorbidities Are Independently Associated With Mortality in Patients With Hepatocellular Carcinoma.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: March 10, 2026

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Journal for immunotherapy of cancer

Published: August 31, 2025

Functional liver imaging score (FLIS): A prognostic biomarker for acute-on-chronic liver failure and liver-related mortality.

Functional liver imaging score (FLIS): A prognostic biomarker for acute-on-chronic liver failure and liver-related mortality.

Journal: JHEP reports : innovation in hepatology

Published: January 15, 2025

Functional Liver Imaging Score (FLIS): A Prognostic Biomarker for Acute-on-Chronic Liver Failure and Liver-Related Mortality.

Functional Liver Imaging Score (FLIS): A Prognostic Biomarker for Acute-on-Chronic Liver Failure and Liver-Related Mortality.

Journal: JHEP reports : innovation in hepatology

Published: January 15, 2025

Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis.

Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis.

Journal: Journal of hepatocellular carcinoma

Published: December 31, 2024

Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.

Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.

Journal: PloS one

Published: November 06, 2024

Palliative care in terminally ill advanced chronic liver disease patients.

Palliative care in terminally ill advanced chronic liver disease patients.

Journal: Wiener klinische Wochenschrift

Published: May 12, 2024

Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.

Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy.

Journal: Hepatology (Baltimore, Md.)

Published: May 02, 2024

Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma.

Evolution of liver function during immune checkpoint inhibitor treatment for hepatocellular carcinoma.

Journal: United European gastroenterology journal

Published: February 24, 2024

Anaemia is independently associated with mortality in patients with hepatocellular carcinoma.

Anaemia is independently associated with mortality in patients with hepatocellular carcinoma.

Journal: ESMO open

Published: January 30, 2024

Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion.

Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion.

Journal: Cancer imaging : the official publication of the International Cancer Imaging Society

Published: November 01, 2023

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.

Journal: JHEP reports : innovation in hepatology

Published: September 19, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026